The published results of the post-marketing ORAL Surveillance study, which compared the
Janus kinase (JAK) inhibitor tofacitinib with anti-TNF therapy in older patients with …

Cytokines function as communication tools of the immune system, serving critical functions
in many biological responses and shaping the immune response. When cytokine production …

Introduction The aim of this work is to evaluate baricitinib safety with respect to venous
thromboembolism (VTE), major adverse cardiovascular events (MACE), and serious …

Objective To assess and compare the incidence of venous thromboembolism (VTE) in
patients with rheumatoid arthritis (RA) treated with Janus kinase inhibitors (JAKi), tumour …

Objectives To assess the risk of major adverse cardiovascular events (MACEs) and venous
thromboembolism events (VTEs) among patients initiating a Janus kinase inhibitor …

New evidence for the treatment of rheumatoid arthritis (RA) has emerged during the last
year. Specifically, updated guidelines on pharmacological and non-pharmacological …

Ulcerative colitis (UC), a relapsing-remitting chronic inflammatory bowel disease (IBD), has
a variable natural course but potentially severe disease course. Since the development of …

Inflammatory bowel diseases, comprising ulcerative colitis (UC) and Crohn's disease, are
chronic, immune-mediated and progressive inflammatory disorders affecting the …

Janus kinase (JAK) inhibitors have been developed as disease-modifying antirheumatic
drugs. Despite the positive therapeutic impacts of JAK inhibitors, concerns have been raised …

Objectives To perform a systematic literature review (SLR) concerning the safety of synthetic
(s) and biological (b) disease-modifying antirheumatic drugs (DMARDs) to inform the 2022 …